Candesartan cilexetil in children with hypertension or proteinuria: Preliminary data

Pediatric Nephrology

Volumn 21, Issue 10, 2006, Pages 1480-1482

  Simonetti, Giacomo D ^a   Vigier, Rodo O ^a   Konrad, Martin ^a   Rizzi, Mattia ^a   Fossali, Emilio ^b   Bianchetti, Mario G ^c,d  

^a UNIVERSITY OF BERN   (Switzerland)

^b Clinica Pediatrica De Marchi   (Italy)

^c OSPEDALE SAN GIOVANNI   (Switzerland)

^d SAN GIOVANNI HOSPITAL   (Switzerland)

Author keywords

Candesartan; Child; Hypertension; Proteinuria

Indexed keywords

ALBUMIN; AMLODIPINE; CANDESARTAN HEXETIL; CREATININE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; NIFEDIPINE; PROPRANOLOL;

ADOLESCENT; ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DOSE CALCULATION; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERKALEMIA; HYPERTENSION; INFANT; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYPERTENSION; INFANT; LOSARTAN; MALE; PROTEINURIA; TABLETS; TETRAZOLES;

EID: 33747833400     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-006-0144-0     Document Type: Article

References (15)

1. Hilgers KF, Dotsch J, Rascher W, Mann JF (2004) Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both? Pediatr Nephrol 19:956-961
2. Cheung BM, Cheung GT, Lauder IJ, Lau CP, Kumana CR (2006) Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J Hum Hypertens 20:37-43
3. 1-Rezeptor-Antagonisten. Dtsch Med Wochenschr 128:2315-2318 (Erratum in: Dtsch Med Wochenschr 129:646)
4. von Vigier RO, Zberg PM, Teuffel O, Bianchetti MG (2000) Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease. Eur J Pediatr 159:590-593
5. Franscini LM, von Vigier RO, Pfister R, Casaulta-Aebischer C, Fossali E, Bianchetti MG (2002) Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases. Am J Hypertens 15:1057-1063
6. Gartenmann AC, Fossali E, von Vigier RO, Simonetti GD, Schmidtko J, Edefonti A, Bianchetti MG (2003) Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. Kidney Int 64:1450-1454
7. Ellis D, Vats A, Moritz ML, Reitz S, Grosso MJ, Janosky JE (2003) Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. J Pediatr 144:834-835
8. Ellis D, Moritz ML, Vats A, Janosky JE (2004) Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. Am J Hypertens 17:928-935
9. Shahinfar S, Cano F, Soffer BA, Ahmed T, Santoro EP, Zhang Z, Gleim G, Miller K, Vogt B, Blumer J, Briazgounov I (2005) A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens 18:183-190
10. Nahata MC (1999) Lack of pediatric drug formulations. Pediatrics 104:607-609
11. Nevins TE (2005) "Why do they do that?" The compliance conundrum. Pediatr Nephrol 20:845-848
12. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555-576
13. Palmer BF (2003) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: What to do if the serum creatinine and/or serum potassium concentration rises. Nephrol Dial Transplant 18:1973-1975
14. Tóth-Heyn P, Drukker A, Guignard JP (2000) The stressed neonatal kidney: From pathophysiology to clinical management of neonatal vasomotor nephropathy. Pediatr Nephrol 14:227-239
15. Alwan S, Polifka JE, Friedman JM (2005) Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 73:123-123